ENTRY       D09731                      Drug
NAME        Crizotinib (JAN/USAN/INN);
            Xalkori (TN)
PRODUCT     XALKORI (Pfizer Laboratories Div Pfizer)
FORMULA     C21H22Cl2FN5O
EXACT_MASS  449.1185
MOL_WEIGHT  450.3367
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG03136  ALK inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02925  CYP3A5 substrate
            Metabolizing enzyme inhibitor
             DG02892  CYP2B6 inhibitor
             DG02852  CYP3A/CYP3A4 inhibitor
            Transporter inhibitor
             DG01622  ABCB1 inhibitor
             DG02908  SLC22A1 inhibitor
             DG02863  SLC22A2 inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01ED01
            Product: D09731<JP/US>
EFFICACY    Antineoplastic, Tyrosine kinase inhibitor
  DISEASE   Non-small cell lung cancer (ALK or ROS1-positive) [DS:H00014]
            Anaplastic large cell lymphoma (ALK-positive) [DS:H01601]
            Inflammatory myofibroblastic tumor (ALK-positive)
TARGET      EML4-ALK [HSA_VAR:238v1] [HSA:238] [KO:K05119]
            ROS1* [HSA_VAR:6098v1] [HSA:6098] [KO:K05088]
  PATHWAY   hsa05200(238)  Pathways in cancer
            hsa05223(238)  Non-small cell lung cancer
METABOLISM  Enzyme: CYP3A4 [HSA:1576], CYP3A5 [HSA:1577]
INTERACTION CYP inhibition: CYP2B6 [HSA:1555], CYP3A [HSA:1576 1577 1551]
            Transporter inhibition: ABCB1 [HSA:5243], SLC22A1 [HSA:6580], SLC22A2 [HSA:6582]
STR_MAP     map07045  Antineoplastics - protein kinase inhibitors
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01ED Anaplastic lymphoma kinase (ALK) inhibitors
                 L01ED01 Crizotinib
                  D09731  Crizotinib (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Crizotinib
                D09731  Crizotinib (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D09731  Crizotinib (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG03136  ALK inhibitor
                D09731  Crizotinib
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D09731  Crizotinib
              DG02925  CYP3A5 substrate
               D09731  Crizotinib
             Metabolizing enzyme inhibitor
              DG02892  CYP2B6 inhibitor
               D09731  Crizotinib
              DG02852  CYP3A/CYP3A4 inhibitor
               D09731  Crizotinib
             Transporter inhibitor
              DG01622  ABCB1 inhibitor
               D09731  Crizotinib
              DG02908  SLC22A1 inhibitor
               D09731  Crizotinib
              DG02863  SLC22A2 inhibitor
               D09731  Crizotinib
            Drug classes [BR:br08332]
             Antineoplastic
              DG03136  ALK inhibitor
               D09731  Crizotinib
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               INSR family
                ROS1* [HSA_VAR:6098v1]
                 D09731  Crizotinib (JAN/USAN/INN) &lt;JP/US&gt;
               ALK family
                EML4-ALK [HSA_VAR:238v1]
                 D09731  Crizotinib (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09731
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09731
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09731
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09731
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D09731
             Drug transporters
              D09731
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D09731
DBLINKS     CAS: 877399-52-5
            PubChem: 124490471
            ChEBI: 64310
            PDB-CCD: VGH
            LigandBox: D09731
ATOM        30
            1   C8x C    15.1200  -18.3400
            2   C8y C    15.1200  -19.7400
            3   C8x C    16.3100  -20.4400
            4   C8y C    17.5700  -19.7400
            5   C8y C    17.5700  -18.3400
            6   N5x N    16.3100  -17.6400
            7   N1a N    18.7600  -17.6400
            8   O2a O    18.7600  -20.4400
            9   C1c C    19.9500  -19.7400
            10  C8y C    21.1400  -20.4400
            11  C8y C    21.1400  -21.8400
            12  C8x C    22.4000  -22.5400
            13  C8x C    23.5900  -21.8400
            14  C8y C    23.5900  -20.4400
            15  C8y C    22.4000  -19.7400
            16  X   Cl   22.4000  -18.3400
            17  X   F    24.7800  -19.7400
            18  X   Cl   19.9500  -22.5400
            19  C1a C    19.9500  -18.3400
            20  C8y C    13.9300  -20.4400
            21  C8x C    12.8100  -19.6700
            22  N5x N    11.6900  -20.4400
            23  N4y N    12.1100  -21.7700
            24  C8x C    13.5100  -21.7700
            25  C1y C    10.9200  -22.4700
            26  C1x C     9.7300  -21.7700
            27  C1x C     8.4700  -22.4700
            28  N1x N     8.4700  -23.8700
            29  C1x C     9.6600  -24.5700
            30  C1x C    10.9200  -23.8700
BOND        33
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     5   7 1
            8     4   8 1
            9     8   9 1
            10    9  10 1
            11   10  11 2
            12   11  12 1
            13   12  13 2
            14   13  14 1
            15   14  15 2
            16   10  15 1
            17   15  16 1
            18   14  17 1
            19   11  18 1
            20    9  19 1 #Down
            21    2  20 1
            22   20  21 1
            23   21  22 2
            24   22  23 1
            25   23  24 1
            26   20  24 2
            27   23  25 1
            28   25  26 1
            29   26  27 1
            30   27  28 1
            31   28  29 1
            32   29  30 1
            33   25  30 1
///
